Skip to main content
. 2023 Aug 29;13:1227036. doi: 10.3389/fonc.2023.1227036

Table 4.

Adverse events.

Parameters SC + ePDT
(N = 22)
SC + eRFA
(N = 28)
SC + ePDT + eRFA
(N = 13)
P-value
N % N % N %
Leucopenia 4 19.0% 5 17.9% 3 23.1% 0.917
Thrombopenia 11 52.4% 8 28.6% 2 15.4% 0.106
Anemia 12 57.1% 11 39.3% 3 23.1% 0.231
Neutropenia 7 33.3% 5 17.9% 2 15.4% 0.434
Other hematotoxic side effects 0 0.0% 3 10.7% 0 0.0% 0.147
ALT elevation 7 33.3% 3 10.7% 3 23.1% 0.178
AST elevation 1 4.8% 0 0.0% 0 0.0% 0.389
Ascites 3 14.3% 3 10.7% 1 7.7% 0.889
Hepatic dysfunction 0 0.0% 2 7.1% 0 0.0% 0.285
Anorexia 2 9.5% 2 7.1% 1 7.7% 0.968
Fatigue 1 4.8% 2 7.1% 0 0.0% 0.626
Nausea 1 4.8% 6 21.4% 2 15.4% 0.236
Vomit 2 9.5% 5 17.9% 2 15.4% 0.664
Creatinine elevation 0 0.0% 2 7.1% 0 0.0% 0.296
Chronic kidney failure 2 9.5% 1 3.6% 0 0.0% 0.456
Skin rash 1 4.8% 1 3.6% 0 0.0% 0.766
Diarrhea 0 0.0% 2 7.1% 1 7.7% 0.415
Edema 0 0.0% 0 0.0% 1 7.7% 0.120
Mucositis 1 4.8% 0 0.0% 1 7.7% 0.357
Allergic reaction 1 4.8% 1 3.6% 0 0.0% 0.766
Infection without neutropenia 11 52.4% 12 42.9% 3 23.1% 0.366
Infection with neutropenia 0 0.0% 2 7.1% 0 0.0% 0.285
Deep vein thrombosis 1 4.8% 1 3.6% 0 0.0% 0.766
Thromboembolic event 6 28.6% 3 10.7% 0 0.0% 0.072
Hyperbilirubinemia 2 9.5% 2 7.1% 3 23.1% 0.256
Jaundice 1 4.8% 2 7.1% 0 0.0% 0.623
Abdominal pain 6 28.6% 10 35.7% 0 0.0% 0.052
Cholangitis 5 23.8% 17 60.7% 5 38.5% 0.025
Biliary sepsis 5 23.8% 2 7.1% 3 23.1% 0.215
Infection (other than cholangitis) 6 28.6% 3 10.7% 1 7.7% 0.205
Weight loss 0 0.0% 1 3.6% 1 7.7% 0.425
Pains 6 28.6% 7 25.0% 2 15.4% 0.772
Pleural effusion 1 4.8% 1 3.6% 0 0.0% 0.766
Hypertension 1 4.8% 0 0.0% 1 7.7% 0.369
Fever 6 28.6% 4 14.3% 3 23.1% 0.537
Ileus 1 4.8% 0 0.0% 2 15.4% 0.084
Phototoxic reaction 4 18.2% 3 23.1% 1.000

Statistically significant P-Values are displayed in bold values.